3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Multiple Myeloma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Large B-Cell, Diffuse
2
Fallopian Tube Neoplasms
2
Uveal Melanoma
1
Thymoma
1
Solitary Fibrous Tumor, Pleural
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Mesothelioma, Malignant
1
Mediastinal Neoplasms
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Eye Neoplasms
1
Congenital Abnormalities
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Neuroendocrine
1
Burkitt Lymphoma
1
Brenner Tumor
1
Bone Marrow Neoplasms
1
Interventions
fludarabine phosphate
19
Cyclophosphamide
18
Tacrolimus
17
Peripheral Blood Stem Cell Transplantation
17
Mycophenolic Acid
17
Antilymphocyte Serum
14
Busulfan
13
Whole-Body Irradiation
12
Methotrexate
11
Cyclosporine
11
Melphalan
7
mogamulizumab
6
Methylprednisolone
6
Etoposide
6
Bexarotene
6
Sirolimus
5
Radiotherapy
5
Flow Cytometry
5
Filgrastim
5
sargramostim
4
pembrolizumab
4
Vorinostat
4
Transplantation
4
Therapeutics
4
Rituximab
4
Lenalidomide
4
Brentuximab Vedotin
4
Alemtuzumab
4
thymoglobulin
3
romidepsin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, T-Cell, Cutaneous
×
belinostat
×
Clear all
NCT00274651
2015-07-28
PXD101-CLN-6
Valerio Therapeutics
Phase 2
Terminated
53 enrolled
12 charts